论文部分内容阅读
目的探讨新辅助治疗在直肠癌中的应用以及临床疗效。方法选取本院自2010年1月~2011年1月收治的50例直肠癌患者,以其治疗方式为依据将其分为观察组(35例)和对照组(15例),观察组患者行新辅助同期放化疗,对照组行新辅助单纯放疗,对两组患者的临床疗效进行对比。结果观察组患者的治疗总有效率明显高于对照组(P<0.05),两组患者的的局部复发率、保肛率比较差异无统计学意义(P>0.05)。结论给予直肠癌患者新辅助治疗可取得良好的效果,但新辅助同期放化疗相较于新辅助单纯放疗对直肠癌患者的治疗效果更佳,临床效果显著,值得推广和应用。
Objective To explore the application of neoadjuvant therapy in rectal cancer and its clinical efficacy. Methods Fifty patients with rectal cancer who were admitted to our hospital from January 2010 to January 2011 were divided into observation group (35 cases) and control group (15 cases) according to the treatment method. Patients in observation group Neoadjuvant radiotherapy and chemotherapy in the same period, the control group of new adjuvant radiotherapy alone, the clinical efficacy of the two groups were compared. Results The total effective rate of observation group was significantly higher than that of control group (P <0.05). There was no significant difference between the two groups in local recurrence rate and anal sphincter preservation rate (P> 0.05). Conclusions The neoadjuvant therapy for patients with rectal cancer can achieve good results. However, neoadjuvant chemoradiotherapy compared with neoadjuvant radiotherapy alone has a better therapeutic effect on patients with rectal cancer, which is worthy of promotion and application.